ArticlePloS one2015
Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Evaluation of a Novel Multi-Epitope Peptide Vaccine Candidate from LACK, LeIF, GP63, SMT Antigens ofArchives of Razi Institute · 2022Article
- Vaccination in Leishmaniasis: A Review Article.Iranian biomedical journal · 2022Article
- Xanthatin Induces Leishmanicidal Activity by Affecting Carbon Metabolism in Amastigotes.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Immunization againstIranian journal of basic medical sciences · 2019Article
- Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host.PLoS neglected tropical diseases · 2019Review
- Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis.Frontiers in veterinary science · 2019Review
- New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-VirulentFrontiers in immunology · 2018Article
- Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies AgainstFrontiers in immunology · 2018Review
- Preparation of transgenic Iranian lizard Leishmania coding HIL-12.Iranian journal of microbiology · 2017Article
- Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.Frontiers in immunology · 2017Review
- Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.PLoS neglected tropical diseases · 2017Article
- Transfected Babesia bovis Expressing a Tick GST as a Live Vector Vaccine.PLoS neglected tropical diseases · 2016Article
- Post-Genomics and Vaccine Improvement for Leishmania.Frontiers in microbiology · 2016Review
- Evaluation of Cellular Immune Responses in Dogs Immunized with Alum-Precipitated AutoclavedIranian journal of parasitologyArticle
- Article
Corrections and comments
- Retraction · 2019-07-05Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Ethical Violations by Author ·
- Retracted
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine Visceral Leishmaniasis (CVL) is a major veterinary and public health problem caused by Leishmania infantum (L. infantum) in many endemic countries. It is a severe chronic disease with generalized parasite spread to the reticuloendothelial system, such as spleen, liver and bone marrow and is often fatal when left untreated. Control of VL in dogs would dramatically decrease infection pressure of L. infantum for humans, since dogs are the main domestic reservoir. In the past decade, various subunits and DNA antigens have been identified as potential vaccine candidates in experimental animal models, but none has been approved for human use so far. In this study, we vaccinated outbreed dogs with a prime-boost regimen based on recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinase genes (CPA and CPB without its unusual C-terminal extension (CPB-CTE) and evaluated its immunogenicity and protective immunity against L. infantum infectious challenge. We showed that vaccinated animals produced significantly higher levels of IgG2, but not IgG1, and also IFN-γ and TNF-α, but low IL-10 levels, before and after challenge as compared to control animals. Protection in dogs was also correlated with a strong DTH response and low parasite burden in the vaccinated group. Altogether, immunization with recombinant L. tarentolae A2-CPA-CPB-CTE was proven to be immunogenic and induced partial protection in dogs, hence representing a promising live vaccine candidate against CVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.